-
Palbociclib in Tumor–Stroma Drug Response Assays
2026-10-01
Palbociclib and PD0332991 can do more than suppress proliferation: they can function as mechanistic probes in patient-derived tumor–stroma models. This article explains how to use CDK4/6 inhibition, paired organoid–assembloid assays, and orthogonal endpoints to distinguish epithelial drug dependence from microenvironment-mediated resistance.
-
3X (DYKDDDDK) Peptide for ORF Microprotein Studies
2026-10-01
The 3X (DYKDDDDK) Peptide provides a compact, hydrophilic handle for tracking and enriching recombinant microproteins, including candidates emerging from non-canonical ORF research. This guide connects the medulloblastoma findings to practical FLAG-tag workflows while emphasizing controls, metal sensitivity, and troubleshooting limits.
-
Asymmetric Cu Single-Atom Nanozyme in AMI
2026-09-30
The reference study develops a bromine-doped, asymmetrically coordinated Cu single-atom nanozyme that improves reactive oxygen species scavenging through electronic-structure engineering. In an acute myocardial infarction model, the material links oxidative damage control with macrophage reprogramming, regulatory T-cell activity, and suppression of adverse remodeling.
-
Panobinostat (LBH589) Experimental Workflow Guide
2026-09-30
Build reproducible Panobinostat assays for HDAC biology, apoptosis induction, and drug-resistance studies. This guide combines practical dosing and validation steps with a new RNA Pol II degradation-dependent apoptosis framework that helps distinguish transcriptional effects from active death signaling.
-
Streptavidin-FITC for Glycan Adhesion Assays
2026-09-29
Streptavidin-FITC provides a high-affinity route for fluorescently detecting biotinylated targets in glycan–microbe adhesion studies. This guide translates findings on ST3GAL1-driven Fusobacterium nucleatum adhesion into practical assay design, controls, and imaging decisions.
-
Esculetin, CKLF1, and Post-Stroke Repair
2026-09-29
A 2025 Acta Pharmacologica Sinica study identifies CKLF1-mediated neutrophil infiltration as a mechanistic link between post-stroke inflammation and impaired recovery. In a mouse photothrombotic stroke model, esculetin reduced infarction, improved neurological and behavioral outcomes, enhanced motor-network activity, and suppressed the CKLF1/CCR5 inflammatory axis.
-
How Inhibitors Promote p38α Dephosphorylation
2026-09-28
A 2024 preprint reports that selected p38α inhibitors do more than block kinase activity: they stabilize an activation-loop conformation that makes phospho-threonine more accessible to the phosphatase WIP1. Biochemical and crystallographic results suggest a conformation-based route to kinase inactivation, while leaving open how broadly the mechanism applies in cells or to other inhibitor compounds.
-
MHY1485 and the mTOR–Autophagy Decision Point
2026-09-27
Explore how MHY1485 can help translational researchers test the relationship between mTOR signaling and autophagy, with practical guidance for interpreting flux assays and connecting cancer and ovarian models without overextending the evidence.
-
β-Elemene Suppresses 3T3-L1 Adipogenesis via AMPK
2026-09-26
In a 3T3-L1 cell model, β-Elemene reduced MDI-induced lipid accumulation and improved glucose consumption in a dexamethasone-induced insulin-resistance model. The study links these effects to recovery of AMPK pathway activity, offering a cellular mechanism to investigate while leaving causality and relevance to whole-organism obesity unresolved.
-
EV-Delivered ACLY Reprograms TAMs in HCC
2026-09-26
The study identifies hepatocellular carcinoma extracellular vesicles as carriers of ACLY that can redirect monocytes toward immunosuppressive tumor-associated macrophages. Engineered vesicles support a causal role for ACLY-driven palmitate synthesis and checkpoint-protein stabilization, and suggest a macrophage-focused strategy that may complement PD-1/PD-L1 blockade in experimental HCC.
-
Dabigatran Etexilate: Oral Direct Thrombin Inhibition
2026-09-25
Blommel and Blommel review dabigatran etexilate as an oral prodrug that produces rapid, predictable anticoagulation through direct thrombin inhibition, without relying on cytochrome P450 metabolism. The review explains its potential advantages over older anticoagulants while emphasizing renal-function-based dosing, bleeding risk, and the limits of the evidence available at publication.
-
Biotin Azide for Probing Lipid-Regulated Wnt Signaling
2026-09-25
Biotin Azide offers a click-chemistry route for capturing alkynylated biomolecules, but its value depends on matching the labeling strategy to the biological question. This article translates findings on cholesterol-regulated Frizzled5 signaling into a careful assay-design framework—and clarifies what biotin capture can and cannot establish.
-
N1-Methylpseudouridine in mRNA Workflows
2026-09-24
N1-Methylpseudouridine can be a useful variable when optimizing mRNA-driven gene activation, but assay success depends on distinguishing the free nucleoside from the triphosphate substrate required for in vitro transcription. This guide connects modified-mRNA design to CRISPRa splice assays, with practical controls for separating improved translation from changes in transcription or cell stress.
-
Ko 143 and BCRP: From Efflux to Exposure
2026-09-24
Ko 143 is a selective BCRP inhibitor for studying how ABCG2-mediated efflux shapes cellular drug response and systemic exposure. This article connects cancer-resistance experiments with quercetin pharmacokinetic findings to show how to distinguish transporter effects from metabolism and formulation effects.
-
Calpain Inhibitor I, ALLN: Practical Workflow
2026-09-23
Calpain Inhibitor I, ALLN (SKU A2602) provides a biochemical tool for studying calpain I/II and cathepsin B/L inhibition in apoptosis, inflammation, and ischemia-reperfusion workflows. It is intended for controlled scientific research only, not for diagnostic, therapeutic, or clinical use, and cellular or animal dosing must be optimized empirically.